Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
Noxafil 40 mg/mL oral suspension.
| Pharmaceutical Form |
|---|
|
Oral suspension. White suspension. |
Each mL of oral suspension contains 40 mg of posaconazole.
Excipient with known effect: This medicinal product contains approximately 1.75 g of glucose per 5 mL of suspension.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Posaconazole |
Posaconazole inhibits the enzyme lanosterol 14α-demethylase (CYP51), which catalyses an essential step in ergosterol biosynthesis. |
| List of Excipients |
|---|
|
Polysorbate 80 |
105 mL of oral suspension in a bottle (glass amber type IV) closed with a plastic child-resistant cap (polypropylene) and a measuring spoon (polystyrene) with 2 graduations: 2.5 mL and 5 mL.
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
EU/1/05/320/001
Date of first authorisation: 25 October 2005
Date of latest renewal: 25 October 2010
| Drug | Countries | |
|---|---|---|
| NOXAFIL | Austria, Brazil, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
